Daniel Hübschmann

2 weeks ago | nature.com | Andreas Mock |Peter Horak |Frederick Klauschen |Melanie Boerries |Simon Kreutzfeldt |Daniel Hübschmann | +6 more

AbstractSalivary gland cancers are rare, diverse malignancies characterized by poor response to immunotherapy. The tumor immune environment in these cancers remains poorly understood. To address this, we perform an integrative analysis of the tumor immune microenvironment in a large cohort of advanced salivary gland cancer samples. Most tumors exhibit low immune activity with limited immune cell infiltration.

Oct 2, 2023 | nature.com | Peter-Martin Bruch |Tobias Roider |Claudia D. Baldus |Hubert Serve |Daniel Hübschmann |Carsten Müller-Tidow | +3 more

AbstractEx vivo drug response profiling is a powerful tool to study genotype–drug response associations and is being explored as a tool set for precision medicine in cancer. Here we conducted a prospective non-interventional trial to investigate feasibility of ex vivo drug response profiling for treatment guidance in hematologic malignancies (SMARTrial, NCT03488641). The primary endpoint to provide drug response profiling reports within 7 d was met in 91% of all study participants (N = 80).